PDE5A and hypoplastic left heart syndrome: While the primary target of PDE5i therapy in SV is the pulmonary vasculature, it has been shown that PDE5 is expressed in the failing myocardium of HLHS patients, suggesting PDE5i may have therapeutic effects on the myocardium directly.